Ascentage Pharma Group International vs Evotec
AAPG and EVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and EVO compare
Evotec grew revenue faster over the last twelve months (−1.1% versus −41.5% for Ascentage Pharma Group International).
Evotec scores higher on the StockData Score (4 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | EVO |
|---|---|---|
| Size and price | ||
| Share price | $15.00 | $1.69 |
| Change, 1 year | −53.7% | −43.5% |
| Change, 5 years | – | −92.9% |
| Beta (5Y) | 0.81 | 1.26 |
| Employees | 767 | 4,553 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −41.5% | −1.1% (better) |
| Revenue growth, 5Y average | – | 9.5% |
| Profitability | ||
| Gross margin | 91.5% (better) | 14.5% |
| Operating margin | – | −7.1% |
| Net margin | −216% | – |
| FCF margin | −209% | −10.4% (better) |
| Return on equity | −156% | – |
| Return on invested capital | – | −7.7% |
| Financial health | ||
| Debt / equity | 1.50 | 0.10 (better) |
| Net debt / EBITDA | – | −7.79 |
| Current ratio | 1.79 | 2.07 (better) |
| Ownership | ||
| Held by institutions | 0.00% | 1.8% |
| Held by insiders | 13.0% | 17.1% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- EVO stock overview
- EVO income statement
- EVO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.